127 related articles for article (PubMed ID: 15028598)
1. Norepinephrine release is reduced by I(1)-receptors in addition to alpha(2)-adrenoceptors.
Raasch W; Jungbluth B; Schäfer U; Häuser W; Dominiak P
Ann N Y Acad Sci; 2003 Dec; 1009():270-3. PubMed ID: 15028598
[TBL] [Abstract][Full Text] [Related]
2. Modification of noradrenaline release in pithed spontaneously hypertensive rats by I1-binding sites in addition to alpha2-adrenoceptors.
Raasch W; Jungbluth B; Schäfer U; Häuser W; Dominiak P
J Pharmacol Exp Ther; 2003 Mar; 304(3):1063-71. PubMed ID: 12604683
[TBL] [Abstract][Full Text] [Related]
3. Moxonidine displays a presynaptic alpha-2-adrenoceptor-dependent synergistic sympathoinhibitory action at imidazoline-1 receptors.
Schäfer U; Burgdorf C; Engelhardt A; Raasch W; Kurz T; Richardt G
Ann N Y Acad Sci; 2003 Dec; 1009():265-9. PubMed ID: 15028597
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of the inhibition by moxonidine and agmatine on the cardioaccelerator sympathetic outflow in pithed rats.
Cobos-Puc LE; Villalón CM; Ramírez-Rosas MB; Sánchez-López A; Lozano-Cuenca J; Gómez-Díaz B; MaassenVanDenBrink A; Centurión D
Eur J Pharmacol; 2009 Aug; 616(1-3):175-82. PubMed ID: 19527708
[TBL] [Abstract][Full Text] [Related]
5. Receptors involved in moxonidine-stimulated atrial natriuretic peptide release from isolated normotensive rat hearts.
Mukaddam-Daher S; Menaouar A; Gutkowska J
Eur J Pharmacol; 2006 Jul; 541(1-2):73-9. PubMed ID: 16774751
[TBL] [Abstract][Full Text] [Related]
6. Involvement of presynaptic imidazoline receptors in the alpha 2-adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives.
Göthert M; Molderings GJ
Naunyn Schmiedebergs Arch Pharmacol; 1991 Mar; 343(3):271-82. PubMed ID: 1678140
[TBL] [Abstract][Full Text] [Related]
7. Presynaptic imidazoline receptors and non-adrenoceptor [3H]-idazoxan binding sites in human cardiovascular tissues.
Molderings GJ; Likungu J; Jakschik J; Göthert M
Br J Pharmacol; 1997 Sep; 122(1):43-50. PubMed ID: 9298527
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological analysis of the cardiac sympatho-inhibitory actions of moxonidine and agmatine in pithed spontaneously hypertensive rats.
Cobos-Puc LE; Sánchez-López A; Centurión D
Eur J Pharmacol; 2016 Nov; 791():25-36. PubMed ID: 27565220
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the involvement of central I1 imidazoline receptor in ethanol counteraction of clonidine hypotension in spontaneously hypertensive rats.
El-Mas MM; Abdel-Rahman AA
J Cardiovasc Pharmacol; 2001 Sep; 38(3):417-26. PubMed ID: 11486246
[TBL] [Abstract][Full Text] [Related]
10. Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction.
Raasch W; Schäfer U; Qadri F; Dominiak P
Br J Pharmacol; 2002 Feb; 135(3):663-72. PubMed ID: 11834614
[TBL] [Abstract][Full Text] [Related]
11. Dual effect of agmatine in the bisected rat vas deferens.
Santos WC; Smaili SS; Jurkiewicz A; Piçarro I; Garcez-do-Carmo L
J Pharm Pharmacol; 2003 Mar; 55(3):373-80. PubMed ID: 12724044
[TBL] [Abstract][Full Text] [Related]
12. Role of I(1)-imidazoline receptors and alpha2-adrenoceptors in hemodynamic effects of moxonidine administration into the rostroventrolateral medulla.
Khokhlova ON; Murashev AN; Medvedev OS
Bull Exp Biol Med; 2001 Apr; 131(4):336-9. PubMed ID: 11550020
[TBL] [Abstract][Full Text] [Related]
13. Effect of moxonidine on the uveoscleral outflow: role of alpha2-adrenoceptors or i1 imidazoline receptors.
Yang J; Sun N; Xiong Q; Yang R
Curr Eye Res; 2009 Apr; 34(4):287-96. PubMed ID: 19373577
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands.
Boronat MA; Olmos G; García-Sevilla JA
Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: an in vivo and in vitro electrophysiological study.
Ugedo L; Pineda J; Ruiz-Ortega JA; Martín-Ruiz R
Br J Pharmacol; 1998 Dec; 125(8):1685-94. PubMed ID: 9886760
[TBL] [Abstract][Full Text] [Related]
16. Influence of imidazolines on catecholamine release in pithed spontaneously hypertensive rats.
Häuser W; Gütting J; Nguyen T; Dominiak P
Ann N Y Acad Sci; 1995 Jul; 763():573-9. PubMed ID: 7677377
[TBL] [Abstract][Full Text] [Related]
17. alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice.
Tolentino-Silva FP; Haxhiu MA; Waldbaum S; Dreshaj IA; Ernsberger P
Brain Res; 2000 Apr; 862(1-2):26-35. PubMed ID: 10799665
[TBL] [Abstract][Full Text] [Related]
18. Prototypical imidazoline-1 receptor ligand moxonidine activates alpha2-adrenoceptors in bulbospinal neurons of the RVL.
Hayar A; Guyenet PG
J Neurophysiol; 2000 Feb; 83(2):766-76. PubMed ID: 10669492
[TBL] [Abstract][Full Text] [Related]
19. Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice.
Fairbanks CA; Wilcox GL
J Pharmacol Exp Ther; 1999 Jul; 290(1):403-12. PubMed ID: 10381806
[TBL] [Abstract][Full Text] [Related]
20. Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors.
Schäfer U; Burgdorf C; Engelhardt A; Kurz T; Richardt G
J Pharmacol Exp Ther; 2002 Dec; 303(3):1163-70. PubMed ID: 12438540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
